Rosen Law Firm Investigates TransMedics Group
Analysis based on 12 articles · First reported Aug 04, 2026 · Last updated Aug 11, 2026
The investigation could negatively affect investor confidence in TransMedics, potentially impacting its stock price. If a lawsuit is filed and succeeds, it could result in financial penalties or governance changes for the company.
Rosen Law Firm, a global investor rights law firm, announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ transplant systems. The investigation was announced on August 5, 2026, and continued through August 11, 2026. Rosen Law Firm is encouraging shareholders of TransMedics to contact them to join the investigation. The firm has a track record of securities class actions and shareholder derivative litigation. The investigation may lead to a securities class action or derivative lawsuit against the company's directors and officers.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard